RA CAPITAL MANAGEMENT, L.P.

Position in TSHA — Taysha Gene Therapies, Inc.

CIK 1346824 BOSTON, MA

Position in TSHA

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$105,293,746

-$24,262,318 QoQ

Shares Held

23,555,648

0.0% QoQ

Ownership

8.20%

of shares outstanding

% of Portfolio

1.12%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2023

9 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

RA CAPITAL MANAGEMENT, L.P. holds $9,134,713,488 across 74 Biotechnology names. TSHA ranks #20 (1.2% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ASND	Ascendis Pharma A/S	10,281,496	$2,351,686,580
2	PCVX	Vaxcyte, Inc.	11,474,599	$666,788,947
3	RYTM	Rhythm Pharmaceuticals, Inc.	6,666,837	$579,814,813
4	TYRA	Tyra Biosciences, Inc.	12,198,625	$467,207,337
5	SION	Sionna Therapeutics, Inc.	9,905,045	$397,093,254
6	EWTX	Edgewise Therapeutics, Inc.	10,428,437	$328,495,765
7	NAMS	NewAmsterdam Pharma Co N.V.	9,550,191	$305,701,613
8	NUVL	Nuvalent, Inc.	2,534,145	$259,623,155

9 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$105,293,746	23,555,648	0.0%	Shares	Sole	2026-05-15
2025-12-31	$129,556,064	23,555,648	0.0%	Shares	Sole	2026-02-17
2025-09-30	$77,026,968	23,555,648	0.0%	Shares	Sole	2025-11-14
2025-06-30	$54,413,546	23,555,648	+116.7%	Shares	Sole	2025-08-14
2025-03-31	$15,112,779	10,872,503	0.0%	Shares	Sole	2025-05-15
2024-12-31	$18,809,430	10,872,503	0.0%	Shares	Sole	2025-02-14
2024-09-30	$21,853,731	10,872,503	0.0%	Shares	Sole	2024-11-14
2024-06-30	$24,354,406	10,872,503	-41.1%	Shares	Sole	2024-08-14
2023-12-31	$32,696,330	18,472,503	—	Shares	Sole	2024-02-14
No filing history on record for this holder in this stock.